Jump to content

2-(Ethylamino)-1,2-diphenylethanone

Add links
From Wikipedia, the free encyclopedia
(Redirected from Βk-Ephenidine)

2-(Ethylamino)-1,2-diphenylethanone
Clinical data
ATC code
  • None
Identifiers
  • 2-(ethylamino)-1,2-diphenylethanone
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17NO
Molar mass239.318 g·mol−1
3D model (JSmol)
  • CCNC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2
  • InChI=1S/C16H17NO/c1-2-17-15(13-9-5-3-6-10-13)16(18)14-11-7-4-8-12-14/h3-12,15,17H,2H2,1H3
  • Key:NHNVMSYWZNJBOO-UHFFFAOYSA-N

2-(Ethylamino)-1,2-diphenylethanone (also known as α-ethylamino-deoxybenzoin, [α-(Ethylamino)benzyl]-(phenyl)-ketone and βk-Ephenidine) is a chemical compound which was first invented in 1955,[1] researched by ICI in 1969 as an antidepressant,[2] and subsequently claimed by AstraZeneca as an inhibitor of the enzyme 11β-Hydroxysteroid dehydrogenase type 1.[3] No other pharmacological data has been disclosed, though its chemical structure closely resembles that of certain designer drug compounds such as ephenidine and N-ethylhexedrone.

See also

[edit]

References

[edit]
  1. ^ Hinderling R, Prijs B, Erlenmeyer H (1955). "Über α-Alkylamino-ketone". Helvetica Chimica Acta. 38 (6): 1415–1420. doi:10.1002/hlca.19550380613.
  2. ^ GB 1143263, Gilman DJ, "Desyl amines and compositions thereof. gdate = 19 February 1969", assigned to ICI Ltd. 
  3. ^ US Abandoned 2005272036, Barton P, Clarke D, Davies C, Hargreaves R, Pease J, Rankine M, "Ketones", published 8 December 2005, assigned to AstraZeneca AB 
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=2-(Ethylamino)-1,2-diphenylethanone&oldid=1216407351"